1 Supplementary Data

1. Supplementary Methods

3 1.1 Table S1: Bacterial strains and cell lines

Bacterial Strains	Description	Source and Reference
EHEC O157:H7 EDL933	stx1a; stx2a	[1]
EHEC/EAEC O104:H4 11-02027	<i>stx2a,</i> resistances: tetracyclines, streptomycin, trimethoprim/sulphonamides, ampicillin, nalidixic acid, cephalosporins	[2]
<i>C. rodentium</i> DBS770	<i>stx_{2dact}-</i> expressing <i>C. rodentium</i> DBS100 lysogenized with phage \u00f61720a-02	[3]
C600W34	<i>E. coli</i> C600 transduced with phage 933W from EHEC strain EDL933	[4]
C. rodentium stx2d::Gluc (MBK22)	DBS770 stx _{2dact} ::gluc, aphT	This study
C600W34 <i>stx2a::Gluc</i> (JLG5)	C600 W34 stx₂a∷gluc, aphT	This study
Cell lines	Medium	Source
VeroB4	OptiPRO SFM (Gibco) supplemented with 1x glutamine	DSMZ-AC33
LLC-PK1	Medium 199 (Biochrom) supplemented with 5% FBS (Sigma)	ATCC CL-101

1.2 Table S2: Plasmids and Oligonucleotides used in this study.

Plasmids	Description/genotype	Reference		
pKD46	repA101(ts), oriR101, <i>bla</i> , Рагав (<i>gam</i> , <i>bet</i> ,	[5]		
	exo)			
pMBK4	pSB377 stx2aA::gluc, aphT	This study		
pSB377	<i>tetAB,</i> oriR6K	[6]		
pWRG701	High-copy vector, colE1-replicon; carries Gaussia luciferase (glow kinetics) <i>GlucM43LM110L aphT</i> flanked by FRT sequences; ampicillin resistance	kind gift from Roman Gerlach		
Oligonucleotides				
Designation	Sequence (5'-3')	Reference		
Stx2-Gluc fusion Fw	TTTTATATCTGCGCCGGGTCTGGTGCTGA TTACTTCAGCCAAAAGGAACACCTGTATA TGAAACCGACCGAAAACAACGA	This study		
Stx2_Com fusion Rev	ATTAACAGAAGCTAATGCAAATAAAACCG CCATAAACATCTTCTTCATGCTTAACTCCT CGTGTAGGCTGGAGCTGCTTC	This study		
Stx2A outside Fw	AGACGGTCAGGGAAGTTCAG	This study		
Stx2B primer Rev	AATCCGGAGCCTGATTCACA	This study		
DBS770 outside Rev	GCGCGGATCCTTCGAATAAA	This study		
DBS Stx2B dn Rev	TAACAAATTCTCAGTCGGGCA	This study		
Seq Com Rev	TCGGAATAGGAACTAAGGAGGA	This study		
GA DBS Stx2 up Fw	GGCTGACATGGGAATTCCTGCAGCCCGG GGGATCCTCAGTCAGAACGGATGATATTG CAG	This study		
GA DBS Stx2 up Rev	TTCGGTCGGTTTCATATACAGGTGTTCCT TTTGGCTGAAG	This study		
GA DBS GlucKan Fw	AAGGAACACCTGTATATGAAACCGACCGA AAACAACGAAG	This study		
GA DBS GlucKan Rev	AGCTAAGGAAGCTAACGTGTAGGCTGGA GCTGC	This study		
GANewDBS Stx2B dn Fw	GCTCCAGCCTACACGCAGGAGTTAAATAT GAAGAAGATATTTGTAGCGG	This study		
GA DBS Stx2B dn Rev	AAGCTCAATAAAAAGCCCCACCGCGGTG GCGGCCGCACCATGCAGGATTTTTTTT AACAAATTCTCAG	This study		

8 **1.3** Table S3: Antibiotics used in this study.

9 10

Stock solutions including solvent and supplier are listed for all antibiotics used in this study.

Antibiotic	stock solution	Supplier
Azithromycin	100 mg/ml in EtOH	Sigma Aldrich / Merck
Carbenicillin	3 mg/ml in H ₂ O	Carl Roth GmbH + Co. KG
Cefalexin	1 mg/ml in H ₂ O	Sigma Aldrich / Merck
Chloramphenicol	30 mg/ml in DMSO	Carl Roth GmbH + Co. KG
Ciprofloxacin hydrochloride	5 mg/ml in H ₂ O	Sigma Aldrich / Merck
Enrofloxacin	50 μg/ml in DMSO	Sigma Aldrich / Merck
Kanamycin	5 mg/ml in H ₂ O	Carl Roth GmbH + Co. KG
Meropenem	10 mg/ml in H ₂ O	Sigma Aldrich / Merck
Rifampicin	20 mg/ml in DMSO	SERVA Electrophoresis GmbH
Tetracycline	15 mg/ml in H ₂ O	SERVA Electrophoresis GmbH
Trimethoprim	5 mg/ml in DMSO	Sigma Aldrich / Merck
Tigecycline	100 mg/ml in H ₂ O	LKT Laboratories, Inc.
Vancomycin	100 mg/ml in H ₂ O	SERVA Electrophoresis GmbH

11

12 **1.4** Generation of *Gaussia* luciferase reporter strains

13 All reporter strains were generated by λ -Red recombination as described (5). 14 The strains C600W34 and *C. rodentium* DBS770 were transformed with pKD46 (5). The template plasmid pWRG701 was used to amplify reporter gene 15 Gaussia princeps luc with M43L/M110L mutations (here: Gluc) and a 16 17 kanamycin-cassette flanked by Flp/FRT sites (FRT aphT FRT). To create 18 C600W34 *(stx2a::Gluc, a PCR product was amplified using primers Stx2-Gluc)* 19 fusion Fw and Stx2 Com fusion Rev containing the reporter gene and the 20 resistance cassette flanked by regions homologous to ~50-60 bp adjacent to 21 the insertion site immediately upstream of stx2aA and stx2aB. All primer 22 sequences are listed in supplementary Table S2. Correct insertion of the 23 reporter was verified by PCR using the primers Stx2A outside Fw and Stx2B 24 primer Rev and sequencing (additional oligonucleotide: Seq Com Rev). To 25 construct the C. rodentium DBS770 reporter strain mutant, Gibson assembly

26 was used to create a template plasmid containing the reporter gene followed by the kanamycin resistance cassette and flanked by 400 bp regions homo-27 28 logous to the target region in DBS770. The oligonucleotides GA DBS Stx2 up 29 Fw and GA DBS Stx2 up Rev were used to amplify the 400 bp region upstream of *stx2A* and the primers GANewDBS Stx2B dn Fw and GA DBS Stx2B dn Rev 30 were used to amplify the region downstream of *stx2d*A. For both PCR reactions 31 32 genomic DNA of DBS770 was used as a template. The Gluc gene and the Kanamycin cassette were amplified by PCR with the primers GA DBS GlucKan 33 34 Fw and GANewDBS Stx2 Rev with a linearized pWRG701 as the template. The pSB377 backbone was cut via BamHI and Notl. Gibson assembly was per-35 formed with the three purified PCR products and the cut vector using the Gibson 36 37 assembly master mix (NEB) following the manufacturer's instructions. The re-38 sulting plasmid (pMBK4) was linearized and used for λ -Red recombination. 39 Correct insertion of the reporter was verified by PCR using the primers Stx2A 40 outside Fw and DBS770 outside Rev and sequenced (additional primer: Seq Com Rev). 41

42

43 **1.5 Serology**

Upon necropsy, blood was taken by cardiac puncture and serum was prepared
by centrifugation and separation in Microvette[®] 500 Z-Gel tubes (Sarstedt) and
frozen for serology. Blood urea nitrogen (BUN) was measured using a Fuji DRICHEM NX500 automatic dry-chemistry analyzer (Fujifilm Corporation).

48

49 **1.6** Histology and pathological evaluation

50 Colon and kidneys were removed and fixed in Roti-Histofix (Roth) for 24 hours

51 and stored in 70% ethanol until further use. Samples were embedded in paraffin and 3 µm thick sections were stained with hematoxylin-eosin according to 52 standard laboratory procedures. Sections were analyzed randomized and 53 blinded to the experimental groups. Tubulus necrosis was graded as follows: 1 54 = sporadic tubulus necrosis or dilation, 2 = 30-50% of the tubuli show necrosis, 55 3 = more than 50% of the tubuli show necrosis. The colon was scored by 5 56 57 markers as follows: inflammation: 1 = few inflammatory cells in lamina propria, 2 = clearly visible inflammatory cells reaching submucosa, 3 = transmural 58 59 invasion of inflammatory cells. Epithelial erosion: 1 = sporadic erosion of epithelial cells, 2 = clearly visible erosion of epithelial cells, with moderate 60 amounts of sloughed cells in lumen, 3 = thinning of crypt walls and large 61 62 amounts of sloughed cells in lumen. Goblet cell loss: 1 = slightly reduced 63 number of goblet cells, 2 = moderate loss of goblet cells with sporadic increase 64 in size, 3 = severe loss of goblet cells with marked increase in size of goblet cells. Epithelial hyperplasia: 1 = up to 100% increase in thickness, 2 = more 65 than 100% increase in thickness, 3= more than 100% increase in thickness and 66 altered morphology. Area involved: 1= up to 30%, 2= 40-70%, 3= more than 67 70%. 68

69

70 **1.7 References:**

Perna NT, Plunkett G, Burland V, Mau B, Glasner JD, Rose DJ, Mayhew
 GF, Evans PS, Gregor J, Kirkpatrick HA, Pósfai G, Hackett J, Klink
 S, Boutin A, Shao Y, Miller L, Grotbeck EJ, Davis NW, Lim A, Dimalanta
 ET, Potamousis KD, Apodaca J, Anantharaman TS, Lin J, Yen
 G, Schwartz DC, Welch RA, Blattner FR. Genome sequence of

- 76 enterohaemorrhagic *Escherichia coli* O157:H7. Nature. 2001; 409: 52977 533.
- Tietze E, Dabrowski PW, Prager R, et al. Comparative genomic analysis of
 two novel sporadic Shiga toxin-producing *Escherichia coli* O104:H4 strains
 isolated 2011 in Germany. PLoS ONE. 2015; 10(4): e0122074.
- Mallick EM, McBee ME, Vanguri VK, et al. A novel murine infection model
 for Shiga toxin-producing *Escherichia coli*. J Clin Invest. 2012;
 122(11):4012–24.
- O'Brien, Alison D., et al. "Shiga-like toxin-converting phages from *Esche- richia coli* strains that cause hemorrhagic colitis or infantile diarrhea."
 Science. 1984; 226.4675: 694-696.
- 5. Datsenko KA, Wanner B. One-step inactivation of chromosomal genes in
 Escherichia coli K-12 using PCR products. Proc. Natl. Acad. Sci. USA
 2000; 97:6640-6645.
- Mirold, S., W. Rabsch, M. Rohde, S. Stender, H. Tschape, H. Russmann,
 E. Igwe, and W. D. Hardt. Isolation of a temperate bacteriophage encoding
 the type III effector protein SopE from an epidemic *Salmonella typhimurium* strain. Proc. Natl. Acad. Sci. USA 1999; 96:9840-9850.

94

2. Supplementary Figures







131 **Supplementary Figure 2.** Influence of antibiotic treatment of *C. rodentium* ϕ *stx*_{2dact}-132 infected mice on the weight of individual mice.

Weight of each mouse is given for every study group (uninfected, untreated and antibiotics-133 134 treated mice). The weight of each mice at day 0 was set to 100%. The dashed line at 80% 135 indicates the official termination point.





138 **Supplementary Figure 3.** Influence of antibiotic treatment of *C. rodentium* ϕstx_{2dact} -139 infected mice on the bacterial colonization in individual mice.

140 The colonization with *C. rodentium* ϕstx_{2dact} of each mouse on alternate days is given for every 141 study group (uninfected, untreated and antibiotics-treated mice). Colonization was determined 142 by feces count. Each dot represents one mouse, the means are indicated. The dotted line 143 denotes the detection limit of the analysis.